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Introduction
During the last decades, the treatment of acute myeloid 
leukemia (AML) has not significantly changed and the 
outcome has remained largely unsatisfactory [1, 2]. 
Complete remission (CR) can be achieved in 70–80% of 
newly diagnosed AML patients treated with conventional 
induction/consolidation regimens, but relapses still occur 
in 40–50% of cases and, in the end, no more than 30–40% 
of adult AMLs can be cured [2, 3]. Therefore, the opti-
mization of postremission therapy to maintain CR 
 represents the greatest challenge in AML treatment.
Thanks to a wider use of allogeneic stem cell trans-
plantation (allo- SCT), which is the most powerful 
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Abstract
Risk stratification in acute myeloid leukemia (AML) patients using prognostic 
parameters at diagnosis is effective, but may be significantly improved by the 
use of on treatment parameters which better define the actual sensitivity to 
therapy in the single patient. Minimal residual disease (MRD) monitoring has 
been demonstrated crucial for the identification of AML patients at high risk 
of relapse, but the best method and timing of MRD detection are still discussed. 
Thus, we retrospectively analyzed 104 newly diagnosed AML patients, consecu-
tively treated and monitored by quantitative polymerase chain reactions (Q- PCR) 
on WT1 and by multiparametric flow cytometry (MFC) on leukemia- associated 
immunophenotypes (LAIPs) at baseline, after induction, after 1st consolidation 
and after 1st intensification. By multivariate analysis, the factors independently 
associated with adverse relapse- free survival (RFS) were: bone marrow (BM)- 
WT1 ≥ 121/104 ABL copies (P = 0.02) and LAIP ≥ 0.2% (P = 0.0001) (after 
1st consolidation) (RFS at the median follow up of 12.5 months: 51% vs. 82% 
[P < 0.0001] and 57% vs. 81%, respectively [P = 0.0003]) and PB- WT1 ≥ 16/104 
ABL copies (P = 0.0001) (after 1st intensification) (RFS 43% vs. 95% [P < 0.0001]) 
Our data confirm the benefits of sequential MRD monitoring with both Q- PCR 
and MFC. If confirmed by further prospective trials, they may significantly 
improve the possibility of a risk- adapted, postinduction therapy of AML.
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postremission treatment [2], some advances have been 
registered in younger adults with high- risk disease. 
Nowadays, there is general agreement in offering allo- SCT 
in first remission to AML patients falling into the category 
of unfavorable cytogenetics [4]. They account for 15–20% 
of newly diagnosed patients and <5–10% of them may 
become long survivors without allo- SCT [4]. Excluding 
another 15–20% of patients with favorable cytogenetics, 
who can be cured in up to 60–70% of cases without 
allo- SCT [2], in the remaining 40–50% of patients with 
intermediate cytogenetic risk, the therapeutic decision is 
problematic due to their heterogeneity and to the difficulty 
in precisely defining their prognosis. Different clinical (e.g., 
age, secondary AML, extramedullary involvement) and 
laboratory (e.g., white blood cell count, LDH serum levels) 
factors have been identified and correlated with prognosis 
[2], but none of them, neither alone nor in combination, 
has been universally recognized and systematically applied 
to guide risk- adapted therapeutic strategy.
More recently, advances in defining the prognostic rel-
evance of genomic alterations created an enormous ex-
pectation in understanding the biological heterogeneity 
of AML and in guiding the therapy [5]. Unfortunately, 
due to the variety and infrequency of molecular abnor-
malities, the translation of this genomic information into 
clinic is difficult and, as a consequence, AML therapeutic 
strategy based on the molecular data at diagnosis still 
remains controversial for the great majority of patients.
Data reported by the Medical Research Council (MRC) 
and Gruppo Italiano Malattie Ematologiche dell’Adulto 
(GIMEMA) strongly suggest that the use of posttreatment 
factors indicating the speed and quality of response can 
improve the outcome prediction in AML patients [6–12]. 
The MRC study showed that patients who entered CR 
after the 2nd induction course had a worse outcome [6], 
whereas GIMEMA studies showed that assessment of the 
minimal residual disease (MRD) might be a powerful and 
accurate tool to improve risk evaluation, as initially es-
tablished on the basis of cytogenetic and molecular markers 
[8]. In this view, multiparametric flow cytometry (MFC) 
and quantitative polymerase chain reactions (Q- PCR) on 
target genes, such as the WT1 pan- leukemic marker, are 
the techniques which are currently used to evaluate the 
quality of response after chemotherapy- induced morpho-
logical CR [7, 9]. At present, the predictive power of 
each technique and the identification of the most accurate 
time- point for MRD assessment are not well defined and 
still remain open questions. Furthermore, it is a matter 
of debate how and when MRD data should be used in 
the context of the AML treatment program.
The aim of this study was to comparatively analyze 
the predictive impact of sequential MRD monitoring with 
leukemia- associated immunophenotypes (LAIP)- MFC and 
WT1 Q- PCR in a cohort of 104 consecutively treated 
AML patients.
Patients and Methods
Patients
One hundred and four consecutive AML patients admitted 
to the Haematology Department of Spedali Civili in Brescia 
from 2010 to 2013 and consecutively treated with a con-
ventional induction/consolidation treatment program [13] 
were retrospectively analyzed. The clinical and biological 
features of the patients are reported in Table 1. According 
to cytogenetic and molecular European Leukemia Net (ELN) 
criteria [1], 37/104 (36%), 30/104 (29%), 17/104 (16%), and 
20/104 (19%) patients belonged to the low, intermediate- 1, 
intermediate- 2, and high- risk categories, respectively; thus, 
65% of the cases fell in the favorable/intermediate- 1 risk 
ELN categories. At diagnosis, a LAIP- MFC was available in 
80/104 (77%) cases, whereas bone marrow (BM) and pe-
ripheral blood (PB) WT1 Q- PCR was available in 92/104 
(88%) and 70/104 (67%) cases, respectively. Overall, in 46 
cases from BM (n = 12) and PB (n = 34) WT1 levels were 
not assessable due to lack of sample collection (92% of the 
cases) or technical reasons (8% of the cases). Nevertheless, 
all the patients had at least one sample, either from BM or 
PB, available for WT1 quantitative assessment, and WT1 
was always overexpressed in these samples. 21% of patients 
Table 1. Clinical and biological features of 104 AML patients.
N (%)
Median age (range) 59 (18–75)
Sex (male) 59 (57)
Median WBC count/μL (range) 9715 (400–218,700)
Unfavorable cytogenetic2 44 (43)
ELN risk category1
Favorable 37 (36)
Intermediate- 1 30 (29)
Intermediate- 2 17 (16)
High- risk 20 (19)
LAIP at diagnosis 80 (77)
BM- WT1 available at diagnosis2 92 (88)
PB- WT available at diagnosis2 70 (67)
FLT3 ITD mutation 22 (21)
FLT3 TKD mutation 10 (10)
NPM1 mutation (on 99 patients) 42 (42)
NPM1/FLT3ITD mutations (on 100 patients) 14 (14)
Patients addressed to consolidation 93 (83)
Patients addressed to intensification 80 (77)
Patients addressed to allo- SCT 33 (32)
LAIP, leukemia- associated immunophenotype; ITD, internal tandem 
 duplication; PBSC, peripheral blood stem cells.
1According to the ELN criteria [1].
2According to the ELN criteria [15].
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were positive for Flt3 internal tandem duplication, 42% for 
the NPM1 mutation, and 14% for both. The median follow 
up of the study population is 12.5 months (range: 1–47).
Plan of treatment
All the patients, stratified according to the ELN risk [1], 
received a treatment program according to the NILG 
(Northern Italy Leukemia Group) AML- Protocol [13].
Briefly, patients less than 70 years received an induction 
chemotherapy consisting of ICE regimen (idarubicine 
12 mg/m2 per day on days 1, 2, and 3; etoposide 100 
mg/m2 per day on days 1–5; cytarabine 100 mg/sqm 
bid on days 1–7), followed by SPLIT regimen (idarubi-
cine 17.5 mg/m2 per day on days 1 and 8, cytarabine 3 
 g/sqm bid on days 2, 3, 9, 10) in case of no response 
(NR) to ICE; patients older than 70 years were treated 
according to the MICE regimen (mitoxantrone 7 mg/m2 
per day on days 1, 3, 5, cytarabine 100 mg/m2 per day 
continuous infusion on days 1–7, etoposide 100 mg/m2 
per day on days 1, 2, 3). Consolidation treatment included 
one cycle of idarubicine 10 mg/m2 per day on days 1, 
2, and 3 and cytarabine 200 mg/m2 per day on days 1–7, 
followed by one cycle of intermediate- dose cytarabine (2 
g/sqm per day for 4 days) for patients younger than 
70 years and one cycle of mini- ICE regimen followed by 
one cycle of intermediate- dose cytarabine (2 g/sqm per 
day for 3 days) for patients older than 70 years. Both 
consolidation programs were followed by peripheral blood 
stem cell (PBSC) collection. Patients with low and inter-
mediate risk leukemia were addressed to intensification 
phase, which consisted of a maximum of three repetitive 
high- dose cytarabine cycles (at a dose ranging between 2 
and 4 g/sqm per day days 1–5 plus idarubicine 8 mg/
m2 per day on day 1 and 2 or 10 mg/sqm day 1)  followed 
or not by autologous PBSC rescue (maximum of three 
cycles), whereas high- risk patients were addressed to HLA- 
matched allo- SCT.
Concerning our series of patients, after remission 
 induction, 93/104 (83%) and 80/104 (77%) patients 
were addressed to consolidation with PBSC collection and 
intensification with at least one cycle of high- dose  cytarabine 
with autologous PBSC rescue, respectively. 33/104 (32%) 
patients were addressed to allo- SCT (Table 1).
Sequential MRD monitoring
MRD monitoring by LAIP- MFC from BM and by WT1 
Q- PCR from both BM and PB were systematically per-
formed at the following time- points: after induction course, 
after the first consolidation course and after the first 
 intensification course. At each time- point, MRD evaluation 
was performed at the time of recovery from PB cytopenia 
(usually between day +30 and +45 from each chemo-
therapy cycle).
Different combinations of fluorescent- labeled monoclo-
nal antibodies from BD Biosciences (CD7/CD33/CD3/CD2 
/CD34/CD4/CD8/CD45;CD5/CD22/CD19/CD10/CD13 
/CD20/CD33/CD45;CD15/CD34/CD14/CD117/CD33/
CD64/CD11b/CD45; and CD64/CD56/HLA- DR/CD13/
CD34/CD16/CD33/CD45) were used to identify LAIPs on 
erythrocyte- lysed BM samples obtained at the time of 
diagnosis as previously reported [14]. Appropriate isotype- 
matched negative controls served to assess background 
fluorescence intensity. The monoclonal antibody combina-
tions characterizing the LAIP were used for MRD detec-
tion, which was assessed by acquiring 250,000 events. At 
least 20 LAIP- positive events have been considered to 
define MRD- positive sample. At the time of relapse, the 
same combinations of antibodies were applied and 50,000 
events were collected. The analysis was performed on a 
FACSCanto II cytometer and data were analyzed with the 
FACSDiva software (BD Biosciences, San Jose, CA). The 
most frequent observed aberrations were as follows: asyn-
chronous antigen expression (n: 48; 34%), lack of antigen 
expression (n: 36; 25%), lineage infidelity (n: 34; 24%), 
and overexpression (n: 25; 17%). LAIPs most frequently 
obtained were CD33+ CD4+ (13%) and CD33+ CD13− 
(13%). Immunophenotypic shift of the leukemic clone at 
relapse was observed in one case only.
Bone marrow and PB quantitative assessment of WT1 
molecular levels was performed by Q- PCR according to 
the ELN method as previously published [15, 16].
Statistical analysis
Survival distributions (relapse- free survival – RFS) were 
estimated using the Kaplan–Meier method [17]. RFS was 
calculated from the date of 1st remission until the date 
of relapse or death, whichever occurred first. Transplanted 
patients were censored at the time of SCT. Differences 
in RFS were evaluated by log- rank test. Cox proportional 
hazard regression model was used for univariate and 
multivariate analysis of factors associated with RFS. The 
following variables were analyzed for all patients: age, sex, 
FAB subtype, WBC, ELN risk category, unfavorable 
 cytogenetics, morphological/cytogenetic remission after 
induction and biological parameters (LAIP, FLT3- ITD, 
FLT3- TKD, NPM1 mutations, and WT1 expression) at 
the time- points previously indicated. Continuous variables 
were categorized as follows: each variable was first divided 
into four categories at approximately the 25th, 50th, and 
75th percentile. If the hazard ratios (HRs) in 2 or more 
adjacent categories were not substantially different, these 
categories were grouped together. If no clear pattern was 
observed, the median was taken as the cut point. All P 
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values were two- sided and P < 0.05 was considered sta-
tistically significant.
Results
Risk stratification at diagnosis
The patients were stratified at diagnosis according to the 
ELN risk criteria [1]. Neither by univariate nor by mul-
tivariate analysis did ELN risk impact on RFS. Other 
baseline clinical (age and sex), and biological variables 
(WBC count, cytogenetic alone, PB and BM- WT1 level, 
NPM1 mutation and Flt3- ITD/TKD mutation) were in-
cluded in univariate and multivariate analysis, but only 
a WBC count greater than 58.500/mmc was independently 
associated with adverse RFS (HR 4.0; 95% CI 1.4–11.7; 
P = 0.01).
The median level of PB and BM WT1 at diagnosis 
was 1747 and 3621 × 104 ABL copies, respectively. By 
univariate analysis on RFS, at least in our cohort of pa-
tients, none of the two values was able to dissect patients 
at different risk of relapse (HR 1.4 [95% CI 0.4–5.2] – 
P = 0.62 and HR 0.9 [95% CI 0.3–2.3] – P = 0.79, for 
PB and BM, respectively).
No significant association between a peculiar LAIP or 
BM/PB WT1 overexpression and any baseline clinical–
pathological characteristic of the patients was found.
Evaluation of predictive impact of 
postremission sequential MRD monitoring
Postremission predictive impact of MRD monitoring by 
LAIP- MFC and by WT1 Q- PCR on RFS was evaluated 
on the basis of MRD results assessed after induction, 
consolidation, and intensification, as previously stated.
By univariate analysis, BM- WT1 ≥ 295 × 104 ABL cop-
ies (HR 7.8; 95% CI 3.7–16.5 – P < 0.0001) and non-
response (NR) to the first induction course were 
significantly associated with poor prognosis (HR 3.3; 95% 
CI 1.4–7.8; P = 0.005). After the 1st consolidation cycle, 
BM- WT1 ≥ 121 × 104 ABL copies (HR 5.2; 95% CI 
2.4–11.4 – P < 0.0001), PB- WT1 ≥ 18 × 104 ABL copies 
(HR 7.9; 95% CI 3.6–17.4 – P < 0.0001), LAIP ≥ 0.2% 
(HR 3.3; 95% CI 1.6–7.1 – P = 0.001) were associated 
with higher incidence of relapse. After 1st intensification, 
BM- WT1 ≥ 150 × 104 ABL copies (HR 7.8; 95% CI 
3.1–19.4 – P < 0.0001), PB- WT1 ≥ 16 × 104 ABL copies 
(HR 12.2; 95% CI 4.4–33.2 – P < 0.0001), a LAIP ≥ 0.27% 
(HR 4.6; 95% CI 1.9–10.8 – P = 0.0006) significantly 
impaired the RFS (Table 2A).
The results of multivariate analysis are reported in 
Table 2B. After 1st consolidation, BM- WT1 ≥ 121 × 104 
ABL copies (HR 4.1; 95% CI 1.3–13.1 – P = 0.02) and 
LAIP ≥ 0.2% (HR 3.3; 95% CI 1.5–7.0 – P = 0.0001) 
were independently associated with adverse RFS. At the 
median follow up, the RFS of patients with 
BM- WT1 < versus ≥ 121 × 104 ABL copies was 82% 
(95% CI 72- 92) versus 51% (95% CI 30–72) (P < 0.0001, 
Fig. 1A). Similarly, the RFS of patients with LAIP ≥ 0.2% 
versus <0.2% was 81% (95% CI 70–92) versus 57% (95% 
CI 37–77), respectively (P = 0.0003, Fig. 1B). After 1st 
intensification, PB- WT1 ≥ 16 × 104 ABL copies (HR 10.2; 
95% CI 3.2–32.1 – P = 0.0001) was the only independent 
predictive factor for adverse long- term outcome. As a 
consequence, the RFS of patients with PB- WT1 < 
 versus ≥ 16 × 104 ABL copies was 95% (95% CI 88–100) 
Table 2. Predictive impact of postremission sequential MRD- monitoring: results of (a) univariate analysis1 and multivariate anaylsis1.
Time- point
Postinduction Post 1st consolidation Post 1st intensification
Variable1 HR (95% CI) P HR (95% CI) P HR (95% CI) P
(A) Results of univariate analysis
 No response after induction 3.3 (1.4–7.8) 0.005 – – – –
 BM- WT1 ≥ 295 × 104 ABL copies 7.8 (3.7–16.5) <0.0001 – – – –
 BM- WT1 ≥ 121 × 104 ABL copies – – 5.2 (2.4–11.4) <0.0001 – –
 PB- WT1 ≥ 18 × 104 ABL copies – – 7.9 (3.6–17.4) <0.0001 – –
 LAIP ≥ 0.2% – – 3.3 (1.6–7.1) 0.001 – –
 BM- WT1 ≥ 150 × 104 ABL copies – – – – 7.8 (3.1–19.4) <0.0001
 PB- WT1 ≥ 16 × 104 ABL copies – – – – 12.2 (4.4–33.2) <0.0001
 LAIP ≥ 0.27% – – – – 4.6 (1.9–10.8) 0.0006
(B) Results of multivariate anaylsis1
 BM- WT1 ≥ 121 × 104 ABL copies – – 4.1 (1.3–13.1) 0.02 – –
 LAIP ≥ 0.2% – – 3.3 (1.5–7.0) 0.0001 – –
 PB- WT1 ≥ 16 × 104 ABL copies – – – – 10.2 (3.2–32.1) 0.0001
1Significant variables only are reported.
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versus 43% (95% CI 22–64) (P < 0.0001, Fig. 1C). The 
clinical and biological characteristics of the patients with 
BM WT1 > × ≥ 121 × 104/104 ABL and LAIP ≥/< 0.2% 
after 1st consolidation, as well as those of the patients 
with PB- WT1 < / ≥ 16 × 104 ABL copies after 1st 
 intensification were well balanced and no statistically 
 significant differences were observed (see Table S1A, B 
and C).
Univariate and multivariate analysis was also performed 
within each of the different ELN risk categories. By mul-
tivariate analysis, BM- WT1 ≥ 121 × 104 ABL copies after 
the 1st consolidation cycle significantly dissected the 
 patients at high risk of relapse both in the ELN Int- 1 
([HR 14.4; 95% CI 2–119; P = 0.01] and Int- 2 risk  category 
[HR 11.7; 95% CI 1–125]; P = 0.04). Similarly, 
LAIP ≥ 0.2% after the 1st consolidation cycle significantly 
identified the patients at high risk of relapse in the ELN 
Int- 2 risk group only (HR 10.1; 95% CI 1–94; P = 0.04).
Incidence of morphological relapse in MRD- 
positive patients
According to the baseline characteristics, first- line allo- SCT 
was planned as an intensification treatment program in 
ELN high- risk patients. Looking at these patients, they 
represented 20/104 (19%); of these 4 (20%) relapsed and 
18 (90%) were allotransplanted in the first line. Since 
allo- SCT was mandatory for these categories of patients, 
we excluded them from subsequent analysis.
In ELN favorable- risk group, 10/37 (27%) patients 
 relapsed and 1/37 (3%) was transplanted in first remission 
(molecular relapse in NPM1- positive case); 3/37 (8%) were 
transplanted in 2nd CR (Table 3). According to MRD 
positivity assessed after consolidation and after intensifica-
tion we observed that 3/12 (25%) and 4/5 (80%) MRD- 
positive cases relapsed, respectively. The incidence of relapse 
rose to 100% in the two cases with MRD positivity both 
after consolidation and after intensification (Table 3).
Within the ELN intermediate 1–2 risk categories, allo- 
SCT has been offered front- line in selected patients such 
as those primary refractory or with disease non- responsive 
to the 1st induction course or with high- risk molecular 
markers (e.g., Flt3- ITD without NPM1 mutation). ELN 
Intermediate 1–2 risk patients accounted for 47/104 (37%); 
16/47 (34%) relapsed; 7/47 (15%) were transplanted in 
first remission (3 Flt3- ITD positive, 2 AML with extramed-
ullary leukemia, 2 1st induction failure); 7/47 (15%) were 
transplanted after relapse in 2nd CR (Table 3). On the 
basis of MRD positivity (either WT1 Q- PCR or LAIP- 
MFC) measured after consolidation and after 
Figure 1. (A) Relapse- free survival (RFS) of the patients according to BM- WT1 after 1st consolidation. At the median follow up (12.5 months): RFS 
82% (95% CI 72–92) for BM- WT1 < 121/104 ABL copies versus 51% (95% CI 30–72) for BM- WT1 ≥ 121/104 ABL copies (assessment after 1st 
consolidation). (B) RFS of the patients according to Leukemia Associated Immunophenotype (LAIP) after 1st consolidation. At the median follow up 
(12.5 months): RFS 81% (95% CI 70–92) for LAIP ≥ 0.2% versus 57% (95% CI 37–77) for LAIP decrease <0.2% (assessment after 1st consolidation). 
(C) RFS of the patients according to PB- WT1 after intensification (1st cycle). At the median follow up (12.5 months): RFS 95% (95% CI 88–100) for 
PB- WT1 < 16/104 ABL copies versus 43% (95% CI 22–64) for PB- WT1 ≥ 16/104 ABL copies (assessment after postintensification – 1st cycle).
A
C
B
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intensification, we observed that 11/20 (55%) and 11/15 
(73%) MRD- positive cases relapsed, respectively. Moreover, 
9/11 (82%) cases with MRD positivity both after con-
solidation and intensification relapsed (Table 3).
Discussion
In the absence of new and more effective antileukemic 
drugs, the improvement of outcome observed in adult 
AML patients during the last decades has been mainly 
due to efforts in optimizing postremission therapy [2, 3]. 
Two major factors played a role concerning this point: 
the progressively better identification of patients at high 
risk of relapse [1, 18] and, in particular, the more ex-
tensive use of allo- SCT in 1st CR in patients selected on 
the basis of cytogenetic and molecular high- risk markers 
[4]. This last category of patients accounts for 40–50% 
of cases. Therefore, approximately half of AML patients, 
who are included in the ELN low/intermediate risk cat-
egories, are generally excluded from first- line allo- SCT 
intensification procedures in order to avoid the risk of 
high transplant- related mortality.
However, both low and intermediate risk patients at 
diagnosis may eventually relapse in 20–40% of cases and 
they should be retreated before being transplanted in 2nd 
CR, with more resistant disease and suboptimal clinical 
conditions. In our cohort of low and intermediate- risk 
AML patients relapses occurred in 27% and 34% of cases, 
respectively, and only a minority of these patients were 
actually allotransplanted in 2nd CR (Table 3). In view 
of postremission therapy optimization, the evaluation of 
MRD during and after treatment may be a powerful and 
accurate tool to improve risk assignment, as initially es-
tablished in many hematological diseases [19, 20] With 
respect to other diseases, AMLs almost represent an ex-
ception, even if studies of other groups clearly indicate 
that the combination of prognostic parameters detected 
before treatment (cytogenetic/molecular) and during treat-
ment (CR after one or two cycles) may improve outcome 
prediction [6] and that MRD monitoring, as an expression 
of disease debulking and drug sensitivity, may be extremely 
important to guide postremission risk- adapted treatment 
[7, 9–12, 21–26].
In this study, we firstly performed a risk stratification 
of our patients according to the baseline clinical and 
biological characteristics. None of the studied variables 
but a WBC count greater than 58.500/mmc was inde-
pendently associated with adverse RFS (HR 4.0 by mul-
tivariate analysis; 95% CI 1.4–11.7; P = 0.01). The result 
of this analysis may be influenced by the intensive thera-
peutic program adopted in our series, which may have 
hampered the prognostic significance of some commonly 
accepted outcome predictors such as cytogenetics. We then Ta
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focused on the longitudinal monitoring of MRD with 
LAIP- MFC and WT1 Q- PCR on PB and BM simultane-
ously, with the aim of evaluating their usefulness in the 
prediction of relapse, comparing the efficiency of the two 
methods and evaluating the most accurately predictive 
time- point for relapse. Multivariate analysis clearly identi-
fied BM- WT1 ≥ 121 × 104 ABL copies (HR 4.1; P = 0.02) 
and LAIP ≥ 0.2% (HR 3.3; P = 0.0001) after 1st con-
solidation, and PB- WT1 ≥ 16 × 104 ABL copies (HR 
10.2; P = 0.0001) after 1st intensification as associated 
with dismal prognosis (Table 2, Fig. 1).
A potential prospective use of these MRD-positive values 
to plan postremission risk-adapted therapy has been sug-
gested in Table 3. Based on the predictive value of MRD 
monitoring on relapse, 5/37 (19%) ELN favorable- risk 
patients could have been considered for allotransplant in 
1st CR, facing a relapse risk of 25% and 80%, respectively, 
if MRD positivity was detected after consolidation or in-
tensification. Similarly, 22/47 (47%) ELN intermediate- risk 
patients could have been considered for allotransplant in 
1st CR, facing a relapse risk of 55% and 73%, respectively, 
if MRD positivity was detected after consolidation or in-
tensification. Finally, in both ELN groups the persistence 
of MRD positivity after consolidation and intensification 
was predictive of relapse in at least 80% of cases, thus 
supporting the indication of an allotransplant. We are 
aware that the number of patients in each group is rela-
tively small and that any conclusion should be drawn 
carefully, but we think that this approach could be helpful 
to clinicians and patients, in order to better evaluate the 
balance between the risk of relapse and that of an al-
lotransplant, the latter being of benefit when the risk of 
leukemia relapse exceeds 35–40% [27].
MFC on LAIP and WT1 Q- PCR techniques became 
very popular for detecting leukemic cells at submicroscopic 
level, mainly because they offered the opportunity of a 
MRD longitudinal measure [28]. MFC shows the advantage 
of being available in almost all hematological- oriented 
laboratories, it is relatively easy but is operator- dependent, 
is not completely standardized and the immunophenotypic 
shift of the leukemic clone may hamper its power in 
predicting relapse. On the other hand, Q- PCR on target 
genes is easy, highly standardized and relatively cheap, 
but it is applicable mainly in AML patients with known 
molecular aberrations (e.g., molecular rearrangements aris-
ing from chromosomal translocations such as in CBF 
leukemias, or gene mutations such as NPM1 and Flt3- 
ITD), which are observed in a minority of cases [29–31]. 
Nevertheless, the possibility to quantify with Q- PCR the 
WT1 gene, which is overexpressed in up to 80–90% of 
AML cases, overcomes this limit and offers the opportunity 
to monitor a MRD marker in the great majority of pa-
tients, although its specificity in detecting the leukemic 
clone remains controversial. We used both the LAIP- MFC 
and WT1 Q- PCR in order to evaluate the efficiency of 
the two methods and we decided to monitor the MRD 
at a very early time- point (after induction), an intermedi-
ate time- point (after consolidation), and a late time- point 
(at the end of the intensification program). In the end, 
we cannot say that one is clearly better than the other 
and we have seen that both methods are useful to stratify 
patients at high risk of relapse as similarly reported by 
other Authors [32–34]. These results have been confirmed 
by other groups, who reported the power of WT1 moni-
toring in detecting patients at high risk of relapse, but 
no conclusive data are available concerning the cut- off 
for positive versus negative samples, as well as the optimal 
time- point for its assessment [23, 36–43]. Concerning this 
latter point, data coming from the published studies are 
not conclusive. In particular, a very early time- point for 
WT1 monitoring (postinduction) [15, 35, 36–39, 41–43], 
but also a later time- point (postconsolidation or 
 pre- allo- SCT) [38, 41–43] have been reported to signifi-
cantly predict the outcome. Concerning LAIP- MFC sen-
sitivity and efficiency, our data are concordant with those 
reported by the GIMEMA group and suggest that the 
most accurate predictive time- point of MRD assessment 
is probably after consolidation [14, 44]. In particular, we 
have seen that, within favorable and intermediate- risk 
groups, MRD positivity after consolidation predicts relapse 
in about 40% of MRD- positive AML patients, but the 
accuracy of relapse prediction increases to 75% when the 
evaluation of MRD positivity is made after intensification. 
On other hand, other Groups observed that LAIP- MFC 
positivity detected at an earlier time- point (after induc-
tion) is significantly associated with increased relapse risk 
[25, 45, 46].
According to our experience and to the data reported 
in literature, MRD monitoring has to be considered dy-
namically: the more we advance in the treatment program, 
the more the level of MRD positivity is reduced, but at 
the same time, the greater becomes the accuracy of the 
predictive power of MRD positivity on relapse. Only tak-
ing into account the dynamic nature of this phenomenon, 
we can explain the discordance of the cut- off values for 
positive versus negative samples observed by different 
groups. Also in our experience, for example, the predic-
tive value of PB- WT1 ≥ 16 × 104 ABL copies measured 
after 1st intensification is greater than PB- WT1 ≥ 5 × 104 
ABL copies measured before transplantation after comple-
tion of the treatment program, as already published on 
a selected cohort of the same patients [16].
As both LAIP and WT1 monitoring proved to be 
 effective and highly concordant in relapse prediction, any 
of them could be chosen in relationship with the expertise 
and the facilities available in different centers. In the 
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meantime, we think the most important effort is to make 
a good choice in terms of the method used for MRD 
monitoring and good standardization and close monitor-
ing of MRD. As suggested by our data, the accuracy of 
indication to allo- SCT depends on when we detect MDR 
positivity and on the number of time- points (single or 
multiple) used for this detection. Moreover, MDR positiv-
ity as an indicator to allo- SCT intensification should be 
combined with other clinical and biological factors detected 
at disease onset. Only through this integrated system of 
evaluation we think that the treatment program could be 
optimized and customized for each patient.
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